What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
Nov 6, 2024 · Wegovy Q3 sales total $2.5 bln. Beat forecast but group sales weaker than expected. Results soothe investor worries over slowing obesity drug demand. Shares rose nearly 9%, but later reversed ...
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Nov 1, 2024 · (Bloomberg) -- Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and ...
News details - Novo Nordisk
Mar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
News Details - Novo Nordisk
Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ® (semaglutide 2.4 mg) label to reflect data from the SELECT cardiovascular outcomes trial, demonstrating a risk ...
News details - Novo Nordisk
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss …
News Details - Novo Nordisk
Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk added that sales of Wegovy were 79% higher year-on-year in the third quarter, coming in at 17.3 billion Danish kroner. ... The news was taken as a signal that Novo Nordisk's efforts ...